The Antibody Drug Conjugates Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Effective and Targeted Medicines are Gaining Traction
Effective and targeted medicines are urgently required in the worldwide health emergency brought on by the (COVID-19) pandemic. Since antibody therapies are relatively simple to develop in comparison to conventional small-molecular medications and are just as precise as vaccines in focusing on the SARS-CoV-2 coronavirus, they have received a lot of attention recently. Seven SARS-CoV-2 antibodies having 3D structures that have been stored in the Protein Data Bank are reviewed (PDB). The possibility of five 3D antibody structures linked to the SARS-CoV spike (S) protein to neutralize SARS-CoV-2 is also assessed. These antibodies' interactions with the S protein receptor-binding domain (RBD) are contrasted with the interactions between complexes including ACE2 and the RBD.Antibody-Drug Conjugates (ADCs) For Cancer Therapy for Drawing Attention from All over the World
Significant traction has been observed for this market owing to the abundance of newly developed antibody-drug conjugates (ADCs) for cancer therapy, drawing attention from all over the world. Even though finding an appropriate mix of an antibody, a linker, and a payload for an ADC can be quite difficult, as of September 2021, 11 ADCs had received FDA clearance, with eight of those being approved in 2017. In 2020, many mergers and partnerships were recorded in the ADC sector despite the COVID-19 pandemic, demonstrating that Big Pharma is highly interested in this therapeutic approach.What Questions Should You Ask before Buying a Market Research Report?
- How is the antibody drug conjugates market evolving?
- What is driving and restraining the antibody drug conjugates market?
- How will each antibody drug conjugates submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
- How will the market shares for each antibody drug conjugates submarket develop from 2022 to 2032?
- What will be the main driver for the overall market from 2022 to 2032?
- Will leading antibody drug conjugates markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
- Who are the leading players and what are their prospects over the forecast period?
- What are the antibody drug conjugates projects for these leading companies?
- How will the industry evolve during the period between 2020 and 2032? What are the implications of antibody drug conjugates projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the antibody drug conjugates market?
- Where is the antibody drug conjugates market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the antibody drug conjugates market today, and over the next 10 years:
- Our 434-page report provides 184 tables and 242 charts /graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2032 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2032, the new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising antibody drug conjugates prices and recent developments.
Segments Covered in the Report
Market Segment by Payload Type
- MMAE
- DM4
- Camptothecin
- DM1
- MMAF
- Other Payload Type
Market Segment by Technology
- Cleavable Linkers
- Non-Cleavable Linkers
- Other Technology
Market Segment by Linker Type
- VC
- Sulfo-SPDB
- SMCC
- Other Linker Type
- VA
- Hydrazone
Market Segment by Target Antigen
- CD30
- HER2
- CD22
- CD33
- Other Target Antigen
Market Segment by Application
- Blood Cancer
- Breast Cancer
- Ovarian Cancer
- Lung Cancer
- Brain Tumor
- Other Application
North America
- U.S.
- Canada
Europe
- Germany
- Russia
- United Kingdom
- France
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
South America
- Brazil
- Mexico
- Rest of South America
Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of Middle East & Africa
Leading companies and the potential for market growth
- AbbVie Inc. Company
- Astellas Pharma Inc.
- Bayer AG
- Celldex Therapeutics, Inc.
- F. Hoffmann-La Roche Ltd.
- Genentech, Inc.
- Gilead Sciences, Inc.
- ImmunoGen, Inc.
- Lantheus Holdings, Inc.
- Lonza Group AG
- Merck KGaA
- Mersana Therapeutics Inc.
- Pfizer Inc.
- Seagen Inc.
- Takeda Pharmaceutical Company Limited
How will the Antibody Drug Conjugates Market, 2022 to 2032 report help you?
In summary, this 430+ page report provides you with the following knowledge:- Revenue forecasts to 2032 for Antibody Drug Conjugates Market, 2022 to 2032 Market, with forecasts by payload type, technology, linker type, target antigen, application, and company size, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2032 for four regional and 20 key national markets - See forecasts for the Antibody Drug Conjugates Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, Russia, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Antibody Drug Conjugates Market, 2022 to 2032.
Information found nowhere else
With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Antibody Drug Conjugates Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.Table of Contents
1 Report Overview
2 Executive Summary
3 Market Overview
4 Global Antibody Drug Conjugates Market Analysis
5 Global Antibody Drug Conjugates Market Analysis by Technology
6 Global Antibody Drug Conjugates Market Analysis by Payload Type
7 Global Antibody Drug Conjugates Market Analysis by Target Antigen
8 Global Antibody Drug Conjugates Market Analysis by Linker Type
9 Global Antibody Drug Conjugates Market Analysis by Application
10 North America Antibody Drug Conjugates Market Analysis
11 Europe Antibody Drug Conjugates Market Analysis
12 Asia-Pacific Antibody Drug Conjugates Market Analysis
13 Middle East & Africa Antibody Drug Conjugates Market Analysis
14 South America Antibody Drug Conjugates Market Analysis
15 Competitive Landscape
16 Company Profiles
17 Conclusion and Recommendations
Companies Mentioned
- AbbVie Inc. Company
- Astellas Pharma Inc.
- Bayer AG
- Celldex Therapeutics, Inc.
- F. Hoffmann-La Roche Ltd.
- Genentech, Inc.
- Gilead Sciences, Inc.
- ImmunoGen, Inc.
- Lantheus Holdings, Inc.
- Lonza Group AG
- Merck KGaA
- Mersana Therapeutics Inc.
- Pfizer Inc.
- Seagen Inc.
- Takeda Pharmaceutical Company Limited
- Abgenomics International Inc.
- Abzena Plc
- Adc Biotechnology Ltd.
- Affinicon Aps
- Agensys, Inc.
- Ambrx Inc.
- Amgen Inc.
- Antikor Biopharma Ltd.
- Astellas Pharma U.S. Inc.
- AstraZeneca Plc
- Bayer Ag
- Bionavigen
- Bioss Antibodies
- Biotecnol
- Biotest Ag
- Biotest Pharmaceuticals
- Bristol Myers Squibb
- Bristol-Myers Squibb Co.
- Catalent Pharma Solutions
- Celldex Therapeutics Inc.
- Celltrion
- Centrose
- Concortis Biotherapeutics
- Creative Biolabs
- Cytomx Therapeutics Inc.
- Daiichi Sankyo Co. Ltd
- Dalton Pharma Services
- Eli Lilly And Co
- Esperance Pharmaceuticals Inc.
- F. Hoffmann-La-Roche Ag (Roche)
- Formation Biologics
- Genmab A/S
- GlaxoSmithKline Plc
- Heidelberg Pharma GmBH
- Immunomedics Inc.
- Lonza Pharma & Biotech
- MabPlex
- Mersana Therapeutics Inc.
- Millennium Pharmaceuticals Inc. (Now Takeda Oncology)
- Millipore Sigma
- Minakem High Potent
- Morphosys Ag
- Nbe Therapeutics
- Oxford Biotherapeutics
- Pfizer Inc.
- Philogen Spa
- Pierre Fabre
- Progenics Pharmaceuticals Inc.
- Seattle Genetics Inc.
- Sevion Therapeutics
- Sorrento Therapeutics Inc
- Sutro Biopharma Inc.
- Synthon
- Synthon Bv
- Viventia Biotechnologies Inc.
- Zhejiang Medicine Co. Ltd.
- Association of British Pharmaceutical Industry (ABPI)
- Central Drugs Standard Control Organization (CDSCO)
- Department of Health and Family Welfare
- Development and Reform Commission (NDRC)
- South American Commission
- South American Medicines Agency (EMA)
- Food and Drug Administration (US FDA)
- Indian Drug Manufacturer's Association (IDMA)
- International Society of Pharmaceutical Engineering (IPSE)
- Korea Food and Drug Administration (KFDA)
- Korea Pharmaceutical Manufacturer's Association (KPMA)
- Medicines and Healthcare Products Regulatory Agency (MHRA)
- Medicines Manufacturing Industry Partnership (MMIP)
- Ministry of Health (MOH)
- Ministry of Health, Labor and Welfare (MHLW)
- Ministry of Industry and Information Technology (MIIT)
- Pharmaceutical and Medical Devices Agency (PMDA)
- World Health Organization (WHO)